Thyroid stunning in clinical practice: Is it a real problem?

Minerva Endocrinologica

Volumn 34, Issue 1, 2009, Pages 29-36

  Filesi, M ^a   Colandrea, M ^a   Montesano, T ^a   D'Apollo, R ^a   Ronga, G ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Physiology; Radiopharmaceuticals; Thyroid diseases; Thyroid neoplasms; Thyroidectomy

Indexed keywords

IODINE 131; THYROTROPIN; DIAGNOSTIC AGENT; IODINE; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT;

ABLATION THERAPY; HUMAN; HYPERTHYROIDISM; RADIATION DOSE; RADIOISOTOPE THERAPY; REVIEW; THYROID CARCINOMA; THYROID STUNNING; THYROIDECTOMY; WHOLE BODY SCINTISCANNING; ADENOCARCINOMA; METABOLISM; PAPILLARY CARCINOMA; PATHOPHYSIOLOGY; RADIATION EXPOSURE; THYROID GLAND; THYROID TUMOR;

ADENOCARCINOMA, FOLLICULAR; CARCINOMA, PAPILLARY; HUMANS; HYPERTHYROIDISM; IODINE; IODINE RADIOISOTOPES; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; THYROID GLAND; THYROID NEOPLASMS;

EID: 67650345612     PISSN: 03911977     EISSN: 18271634     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994;97:418-28.
2. DeGroot LJ, Kaplan EL, McCormick M, Straus FH. Natural history, treatment and course of papillary thyroid cancer. J Clin Endocrinol Metab 1990;71:414-24.
3. Samaan NA, Schultz PN, Hickey RC, Goepfert H, Haynie TP, Johnson DA et al. The results of various modalities of treatment of differentiated thyroid carcinomas. A retrospective review of 1599 patients. J Clin Endocrinol Metab 1992;75:714-20.
4. Hay ID, Thompson GB, Grant CS, Bergstralh EJ, Dvorak CE, Gorman CA et al. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutive treated patients. World J Surg 2002;26:879-85.
5. Carril JM, Quirce R, Serrano J, Banzo I, Jimenez-Bonilla JF, Tabuenca O et al. Total-body scintigraphy with thallium-201 and iodine-131 in the follow-up of differentiated thyroid cancer. J Nucl Med 1997;38:686-92.
6. Park HM, Park YH, Zhou XH. Detection of thyroid remnant metastasis without stunning: an ongoing dilemma. Thyroid 1997;7:277-80.
7. Muratet J, Daver A, Minier J, Larra F. Influence of scanning doses of iodine-131 on subsequent first ablative treatment outcome in patients operated on for differentiated thyroid carcinoma. J Nucl Med 1998:39:1546-50.
8. Fatourechi V, Hay DD, Mullan BP, Wiseman GA, Eghbali Fatourechi GZ, Thorson LM et al. Are post-therapy radioiodine scans informative and do they influence subsequent therapyof patients with differentiated thyroid cancer? Thyroid 2000;10:573-7.
9. Sherman SI, Tielens ET, Sostre S, Wharam MD JR, Ladenson PW. Clinical utility of post-treatment radioiodine scans in the management of patients with thyroid carcinoma. J Clin Endocrinol Metab 1994;78:629-34.
10. Pacini F, Lippi F, Formica N, Elisei R, Anelli S, Ceccarelli C et al. Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels. J Nucl Med 1987;28:1888-91.
11. Ronga G, Filesi M, Ventroni G, Vestri AR, Signore A. Value of the first serum thyroglobulin level after total thyroidectomy for the diagnosis of metastases from differentiated thyroid carcinoma. Eur J Nucl Med 1999;26:1448-52.
12. Cailleux AF, Baudin E, Travagli JP, Ricard M, Schlumberger M. Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer? J Clin Endocrinol Metab 2000;85:175-8.
13. Sabri O, Zimny M, Schreckenberger M, Meyer-Oelmann A, Reinartz P, Buell U. Does thyroid stunning exist? A model with benign thyroid disease. Eur J Nucl Med 2000;27:1591-7.
14. Rawson RW, Rall JE, Peacock W. Limitations and indications in the treatment of cancer of the thyroid with radioactive iodine. J Clin Endocrinol Metab 1951;1:1128-42.
15. Guiraud-Vitaux F, Feldmann G, Vadrot N, Charles-Gupta S, Durand-Schneider AM, Colas-Linhart N et al. Early ultrastructural injuries in the thyroid of the normal rat radioinduced by diagnostic and/or therapeutic amounts of iodine-131. Cell Mol Biol 2001;47:495-502.
16. Turgut B, Babul A, Ozdemir O, Erselcan T. Evaluation of the cell death pathway and apoptosis stunning effect relationship after low- and high-dose I-131 administrations in rat thyroid tissue. Cancer Biother Radiopharm 2006;21:342-51.
17. Postgard P, Himmelman J, Lindecrona U, Bhogal N, Wiberg D, Berg G et al. Stunning of iodide transport by 131I irradiation in cultured epithelial cells. J Nucl Med 2002;43:828-34.
18. Norden MM, Larsson F, Tedelind S, Carlsson T, Lundh C, Forssel-Aronsson E et al. Down regulation of the sodium/iodide symporter explains 131I-induced thyroid stunning. Cancer Res 2007;67:7512-7.
19. Sisson JC, Avram A-M, Lawson SA, Gauger PG, Doherty GM. The so-called stunning of thyroid disease. J Nucl Med 2006;47:1406-12.
20. Cholewinski SP, Yoo KS, Klieger PS, O'Mara RE. Absence of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I. J Nucl Med 2000;41:1198-202.
21. McDougall IR. 74 MBq radioiodine 131-I does not prevent uptake on therapeutic doses of I-131 (i.e. it does not cause stunning) in differentiated thyroid cancer. Nucl Med Commun 1997;18:861-5.
22. Morris LF, Waxman AD, Braunstein GD. The nonimpact of thyroid stunning: remnant ablation rates in 131I scanned and nonscanned individuals. J Clin Endocrinol Metab 2001;86:3507-11.
23. Bajén MT, Mañé S, Muñoz A, García JR. Effect of a diagnostic dose of 185 MBq 131I on postsurgical thyroid remnants. J Nucl Med 2000;41:2038-42.
24. Dam HQ, Kim SM, Lin HC, Intenzo CM. 131I therapeutic efficacy is not influenced by stunning after diagnostic Whole-Body scanning. Radiology 2004;232:527-33.
25. Coakley AJ. Thyroid stunning. Eur J Nucl Med 1998;25:203-4.
26. Gerard SK. Stunning with 131I diagnostic Whole Body imaging of patients with thyroid cancer. Radiology 2005;234:972-3.
27. Chopra S, Wastie ML, Chan S, Vincent RM, Przeslak A, Perkins AC et al. Assessment of completeness of thyroid ablation by estimation of neck uptake of 131I on whole-body scans: comparison of quantification and visual assessment of thyroid bed uptake. Nucl Med Commun 1996;17:687-91.
28. Brenner W. Is thyroid stunning a real phenomenon or just fiction? J Nucl Med 2002;43:835-36.
29. Hadjieva DT. Quantitative evidence of thyroid stunning in 131I cancer treatment. Nucl Med Rev 2000;3:47-51.
30. Jeevanram RK, Shah DH, Sharma SM, Ganatra RD. Influence of initial large dose on subsequent uptake of therapeuthic radioiodine in thyroid cancer patients. Int J Rad Appl Instrum 1986;13:277-9.
31. Lees W, Mansberg R, Roberts J, Towson J, Chua E, Turtle J. The clinical effects of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I. Eur J Nucl Med Mol Imaging 2002;11:1421-7.
32. Rafat A, Saber MD. Thyroid stunning after diagnostic dose of 185 MBq (5 mCi) iodine-131 in patients with differentiated thyroidal cancer. J Egyptian Nat Cancer Inst 2002;2:153-9.
33. Rosario PWS, Barroso AL, Rezende LL, Padrao EL, Ribeiro Maia FF, Fagundes TA et al. 5 mCi pretreatment scanning does not cause stunning when the administered dose is administered within 72 hours. Arq Bras Endocrinol Metab 2005;49:420-4.
34. Lassman M, Luster M, Hanscheid H, Reiners C. Impact of 131I diagnostic activities on the biokinetics of thyroid remnants. J Nucl Med 2004;45:619-25.
35. Yeung HWD, Humm JL, Larson SM. Radioiodine uptake in thyroid remnants during therapy after tracer dosimetry. J Nucl Med 2000;41:1082-5.
36. Medvedec M. Thyroid stunning in vivo e in vitro. Nucl Med Commun 2005;26:731-5.
37. Hilditch TE, Dempsey MF, Bolster AA, McMenemin RM, Reed NS. Self stunning in thyroid ablation: evidence from comparative studies of diagnostic 131I and 123I. Eur J Nucl Med Mol Imaging 2002;29:783-8.
38. Park HM, Perkins OW, Edmonson JW, Schnute RB, Manatunga A. Influence of diagnostic radioiodines on the uptake of ablative dose of iodine-131. Thyroid 1994;4:49-54.
39. Silberstein EB. Comparison of outcomes after 123I versus 131I preablation imaging before radioiodine ablation in differentiated thyroid carcinoma. J Nucl Med 2007;48:1043-6.
40. Huic D, Medvedec M, Dodig D, Popovic S, Ivancevic D, Pavlinovic Z et al. Radioiodine uptake in thyroid cancer patients after diagnostic application of low-dose I-131. Nucl Med Commun 1996;17:839-42.
41. Doi Sa, Woodhouse NJ - Ablation of the thyroid remnant and 131I dose in differentiated thyroid cancer - Clin Endocrinol 2000;52:765-73.
42. WU HS, Hseu HH, Lin Wy Wang SJ, Liu YC. Decreased uptake after fractionated ablative doses of iodine-131. Eur J Nucl Med Mol Imaging 2005;32:167-73.
43. Arad E, Flannery K, Wilson GA, O'Mara RE. Fractionated doses of radioiodine for ablation of postsurgical thyroid tissue remnants. Clin Nucl Med 1990;15:676-7.
44. Czepczynski R, Ziemnicka K, Baczyk M, Oleksa R, Ruchala M, Sowinski J. Fractionated dosage of radioiodine for the ablation of differentiated thyroid carcinoma. Thyroid 2005;15:1261-5.
45. Hermanska J, Karny M, Zimak J, Jirsa L, Samal M, Vlcek P. Improved prediction of therapeutic adsorbed dose of radioiodine in the treatment of thyroid carcinoma. J Nucl Med 2001;42:1084-90.
46. Morris LF, Waxman AD, Braunstein GD. Thyroid stunning. Thyroid 2003;13:333-40.